Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 3 studies | 27% ± 6% |
Insufficient scRNA-seq data for expression of ASIP at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 99% | 862.12 | 179 / 180 | 66% | 2.72 | 283 / 430 |
skin | 78% | 102.75 | 1408 / 1809 | 41% | 1.62 | 192 / 472 |
kidney | 55% | 18.00 | 49 / 89 | 49% | 2.34 | 439 / 901 |
uterus | 76% | 50.94 | 130 / 170 | 26% | 1.13 | 120 / 459 |
breast | 85% | 59.89 | 388 / 459 | 16% | 0.30 | 174 / 1118 |
heart | 95% | 231.90 | 819 / 861 | 0% | 0 | 0 / 0 |
brain | 12% | 2.37 | 305 / 2642 | 82% | 3.77 | 579 / 705 |
liver | 56% | 15.75 | 126 / 226 | 36% | 0.81 | 146 / 406 |
prostate | 78% | 36.20 | 190 / 245 | 13% | 0.27 | 67 / 502 |
thymus | 34% | 6.56 | 224 / 653 | 49% | 1.29 | 295 / 605 |
esophagus | 12% | 2.40 | 167 / 1445 | 64% | 1.82 | 118 / 183 |
adrenal gland | 49% | 12.99 | 126 / 258 | 22% | 0.98 | 51 / 230 |
bladder | 52% | 11.71 | 11 / 21 | 18% | 0.62 | 91 / 504 |
stomach | 21% | 4.55 | 75 / 359 | 41% | 0.92 | 118 / 286 |
adipose | 62% | 25.83 | 746 / 1204 | 0% | 0 | 0 / 0 |
intestine | 41% | 11.10 | 398 / 966 | 19% | 0.37 | 98 / 527 |
eye | 0% | 0 | 0 / 0 | 51% | 3.28 | 41 / 80 |
lung | 28% | 6.09 | 160 / 578 | 19% | 0.41 | 219 / 1155 |
muscle | 39% | 12.83 | 314 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 34% | 0.60 | 10 / 29 |
tonsil | 0% | 0 | 0 / 0 | 22% | 0.55 | 10 / 45 |
spleen | 20% | 3.29 | 47 / 241 | 0% | 0 | 0 / 0 |
pancreas | 1% | 0.10 | 2 / 328 | 13% | 0.29 | 24 / 178 |
blood vessel | 10% | 3.16 | 127 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 0.15 | 7 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0008343 | Biological process | adult feeding behavior |
GO_0044725 | Biological process | epigenetic programming in the zygotic pronuclei |
GO_0006091 | Biological process | generation of precursor metabolites and energy |
GO_0032438 | Biological process | melanosome organization |
GO_0032402 | Biological process | melanosome transport |
GO_0007267 | Biological process | cell-cell signaling |
GO_0048023 | Biological process | positive regulation of melanin biosynthetic process |
GO_0042438 | Biological process | melanin biosynthetic process |
GO_0009755 | Biological process | hormone-mediated signaling pathway |
GO_0005615 | Cellular component | extracellular space |
GO_0031779 | Molecular function | melanocortin receptor binding |
GO_0031782 | Molecular function | type 4 melanocortin receptor binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005184 | Molecular function | neuropeptide hormone activity |
GO_0031781 | Molecular function | type 3 melanocortin receptor binding |
Gene name | ASIP |
Protein name | Agouti-signaling protein (ASP) (Agouti switch protein) |
Synonyms | AGTIL AGTI ASP |
Description | FUNCTION: Involved in the regulation of melanogenesis. The binding of ASP to MC1R precludes alpha-MSH initiated signaling and thus blocks production of cAMP, leading to a down-regulation of eumelanogenesis (brown/black pigment) and thus increasing synthesis of pheomelanin (yellow/red pigment). In higher primates, agouti may affect the quality of hair pigmentation rather than its pattern of deposition. Could well play a role in neuroendocrine aspects of melanocortin action. May have some functional role in regulating the lipid metabolism with adipocytes. . |
Accessions | P42127 ENST00000374954.4 ENST00000568305.5 |